Boston Scientific Q1 FY26: where the revenue came from and where it went
The whole income statement of Boston Scientific for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jan 1 – Mar 31, 2026
- Reported
- May 1, 2026
Revenue$5.20B
+12% year over year
Gross profit$3.61B
69% margin
Operating profit$1.10B
21% margin
Net profit$1.34B
26% margin
Net profit is larger than what operations earned, because the statement adds $0.24B below it, under Tax benefit and other.
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 5.20 | 100% | +12% |
| Cardiology therapies | 1.24 | 24% | |
| Electrophysiology | 0.91 | 17% | +24% |
| Global endoscopy | 0.74 | 14% | +9% |
| Urology & pelvic health | 0.65 | 13% | +2% |
| Cardiac rhythm management | 0.58 | 11% | +0% |
| Watchman | 0.51 | 10% | +19% |
| Neuromodulation | 0.32 | 6% | +17% |
| Interventional oncology | 0.27 | 5% | |
| Cost of revenue | −1.59 | 31% | |
| Gross profit | 3.61 | 69% margin | +1pp |
| SG&A | −1.78 | 34% | +0pp |
| Other | −0.73 | 14% | +0pp |
| Operating profit | 1.10 | 21% margin | +1pp |
| Tax benefit and other | 0.24 | ||
| Net profit | 1.34 | 26% margin | +11pp |
182 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest